Latest Breaking News On - Nathalie altermatt - Page 2 : comparemela.com

Roche granted FDA Breakthrough Device Designation for blood test measuring Lp(a) – a key marker for hereditary cardiovascular risk

Approximately one in five people worldwide have elevated Lp levels, putting them at increased risk of cardiovascular diseases including myocardial infarction and stroke.1The Roche Diagnostics.

United statesNathalie altermattJay bradnerSabine borngrKarsten kleineRebekka schnellSimon goldsboroughLoren kalmBirgit masjostKirti pandeyYvette petillonSileia urechBruno eschliColl cardiolMatt sauseRoche group

F Hoffmann-La Roche Ltd: Roche granted FDA Breakthrough Device Designation for blood test measuring Lp(a) - a key marker for hereditary cardiovascular risk

Approximately one in five people worldwide have elevated Lp(a) levels, putting them at increased risk of cardiovascular diseases including myocardial infarction and stroke.1The Roche Diagnostics Tina-quant®

United statesMatt sauseSabine borngrKarsten kleineRebekka schnellSimon goldsboroughBirgit masjostYvette petillonJay bradnerNathalie altermattSileia urechLoren kalmKirti pandeyBruno eschliEuropean society of cardiologyCanadian cardiovascular society

FDA grants Breakthrough Therapy Designation to Roche s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

The designation is based on Phase III INAVO120 results, showing the inavolisib-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the.

United statesSan antonioBruno eschliSabine borngrNathalie altermattKarsten kleineSileia urechBirgit masjostLevi garrawayRebekka schnellKirti pandeyLoren kalmYvette petillonSimon goldsboroughNational cancer instituteHead of global product development

F Hoffmann-La Roche Ltd: FDA grants Breakthrough Therapy Designation to Roche s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

The designation is based on Phase III INAVO120 results, showing the inavolisib-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line

United statesSan antonioSileia urechSimon goldsboroughNathalie altermattBruno eschliLevi garrawayRebekka schnellKirti pandeyBirgit masjostLoren kalmSabine borngrKarsten kleineYvette petillonDrug administrationHead of global product development

F Hoffmann-La Roche Ltd: Roche reports positive Phase I results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity

F Hoffmann-La Roche Ltd: Roche reports positive Phase I results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesYvette petillonSimon goldsboroughLevi garrawayKirti pandeySabine borngrRebekka schnellLoren kalmBirgit masjostNathalie altermattSileia urechBruno eschliKarsten kleineRoche groupHead of global product developmentChief medical officer